Table 2.
Major drug combinations used as induction therapy
| Induction | Post ASCT | ||||
|---|---|---|---|---|---|
| Author (reference) | Regimen | ≥VGPR (%) | ≥VGPR (%) | PFS | OS |
| Harousseau (23) | VD | 38 | 54 | 36 mos | 81%@ 3 yrs |
| Cavo (28) | VTD | 62 | 82 | 68% @ 3 yrs | 86% @ 3 yrs |
| Sonneveld (26) | PAD | 42 | 61 | 35 mos | NR |
| Reeder (25) | VCD | 61 | 74 | NR | NR |
| Rajkumar (27) | Rd | 40 | NR | 63% @ 2 yrs | 92% @ 3 yrs |
| Rosinol (29) | VTD | 60 | 46 (CR) | 56.2 mos | 74% @ 4 years |
| Richardson (31) | RVD | 61 | NR | 75% @ 18 mos | 97% @ 18 mos |
VD = bortezomib-dexamethasone; VTD= bortezomib-thalidomide-dexamethasone, PAD=Bortezomib-doxorubicin, dexamethasone ; VCD = bortezomib-cyclophosphamide-dexamethasone; Rd = lenalidomide-low dose dexamethasone; RVD = lenalidomide-bortezomib-dexamethasone; VGPR = very-good partial remission; NR = not reported, PFS = progression-free survival, OS = overall survival